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Purpose: To compare the efficacy between macular laser grid (MLG) photocoagulation and MLG plus intravitreal 
triamcinolone acetonide (IVTA; MLG+IVTA) therapy in diabetic macular edema (DME) patients.
Methods: A prospective, randomized, clinical trial was conducted of DME patients. A total of 60 eyes (54 patients) 
affected by DME were observed for a minimum of 6 months. Thirty eyes of 28 patients who received MLG treatment 
and 30 eyes of 26 patients who received the combined MLG+IVTA treatment were included in the study. Main outcome 
measures were BCVA and central macular thickness (CMT) as measured by optical coherence tomography (OCT) 
at 1, 3, and 6 months after treatment. Additionally, the authors examined retrospectively 20 eyes of 20 patients who 
were treated with only IVTA and compared with the 2 groups (MLG group and MLG+IVTA group).
Results: Baseline BCVA was 0.53±0.32 and CMT was 513.9±55.1 μm in the MLG group. At 1 and 3 months after treat-
ment, the MLG group showed no significant improvement of BCVA and CMT, although there was significant im-
provement after 6 months. In the MLG+IVTA group, the baseline BCVA was 0.59±0.29 and CMT was 498.2±19.8 
μm. After treatment, significant improvement of BCVA and CMT was observed at all follow-up time periods. When 
comparing the MLG group with the MLG+IVTA group, the latter had better results after 1 and 3 months, although at 
6 months, there was no significant difference of BCVA and CMT between the 2 groups. Additionally, the IVTA group 
showed more improvement than the MLG group at 1 and 3 months but showed no significant difference at 6 months. 
In addition, the IVTA group showed no significant difference with the MLG+IVTA group at all follow-up time periods.
Conclusions: For DME patients, the combined MLG+IVTA treatment had a better therapeutic effect than the MLG 
treatment for improving BCVA and CMT at the early follow-up time periods. IVTA treatment alone could be an additional 
alternative therapeutic option to combined therapy.
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Diabetic macular edema (DME) is caused by the injury of 
the internal blood-retinal barrier. The permeability of the retinal 
capillary, the leakage of body fluid and the plasma component 
are increased and retained in the macula, and consequently, 
BCVA is deteriorated.
1 According to the Early Treatment Dia-
betic Retinopathy Study (ETDRS) for the treatment of DME, 
macular laser grid (MLG) photocoagulation has been reported 
to be effective, but despite appropriate treatments, the result of 
a 3-year observation showed a deterioration of BCVA by at least 
3 lines in approximately 15% of the patients.
2-4 Steroids such 
as prostaglandin, that have been used to improve DME, suppress 
the synthesis of cytokines by controlling the inflammatory reac-
tion and thus resulting in the reduction of vascular leakage and 
decreasing macular edema. Hence, the effect of decreasing cen-
tral macular thickness (CMT) and improving BCVA can be ob-
tained. Therefore, in the field of ophthalmology, a 4 mg/0.1 cc 
intravitreal injection of the hydrophobic crystallin cortisone 
triamcinolone acetonide used in inflammatory diseases has 
recently been used for diabetic macular treatment as well as 
various retinal diseases.
5-7 In the present study the effectiveness 
of MLG applied conventionally to DME patients and the com-
bination therapy with MLG plus intravitreal triamcinolone ace-
tonide (IVTA; MLG+IVTA) were compared, and the side effects 
examined in DME patients who did not show distinct focal 
leakage in fluorescein angiography. 
Materials and Methods
1. Research subjects
The study consisted of 60 eyes of 54 patients who visited 
the department of ophthalmology at our hospital with the chief 
complaint of BCVA deterioration diagnosed as DME by fundus 
examination, fluorescein angiography, and optical coherence 
tomography (OCT) from January 2006 to December 2006. The Korean J Ophthalmol Vol.23, No.3, 2009
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Table 1. A baseline comparison between the study groups
Characteristic MLG
* group MLG+IVTA
† group p-value
‡
Age (years, mean±SD) 59.6±10.8 63.6±11.1 0.197
Duration of DM (years, mean±SD)  14.3±7.8 17.0±9.3 0.397
Glycated hemoglobin (%, mean±SD) 10.9±17.2 7.6±1.4 0.313
Intraocular pressure (mmHg, mean±SD) 15.5±3.1 14.5±3.4 0.170
Initial BCVA (logMAR, mean±SD) 0.53±0.32 0.61±0.29 0.224
Initial CMT (μm, mean±SD) 513.9±55.1 498.2±19.8 0.586
* MLG=Macular laser grid photocoagulation; 
† MLG+IVTA=Macular laser grid photocoagulation+intravitreal triamcinolone injection group; 
‡ p-value measuredby Mann-Whitney U test.
patients were divided into 2 groups according to their treatment. 
The first group consisted of 30 eyes of 28 patients treated with 
only MLG, and the second group consisted of 30 eyes of 26 
patients treated with a combination of MLG+IVTA. The patients 
excluded from the present study had retinal vascular occlusion 
(i.e., CRVO, BRVO), vitritis, ARMD, tractional or rhegmato-
genous retinal detachment, vitreous hemorrhage, severe macular 
ischemia, or intraocular treatment during the follow-up obser-
vation. Additionally, 20 eyes of 20 patients who were treated 
only with IVTA were retrospectively examined and compared 
with the other 2 groups.
2. Research methods
(1) Laser photocoagulation (grid laser therapy)
Grid laser therapy was performed after the dilation of the 
subject’s eye (Mydrin-P
Ⓡ administered to the inferior conjunc-
tival sac, at 10-minute intervals, 2 times), and the eye was ane-
sthetized with 2% lidocain hydrochloride. Using a contact lens, 
with a setting of 50-200 μm light intensity and 0.1-0.2 seconds 
exposure time, the intensity was weaker than panretinal photo-
coagulation, and performed approximately at 1 laser burn in-
tervals. The laser was irradiated on the area 500-3000 μm from 
the macular center at the thickened retina showing capillary 
blood vessel occlusion and considered to be the origin of the 
leakage in the focal diffusion leakage area as shown by fluo-
rescence fundus angiography. In other words, the area showing 
initial hyperfluorescence was irradiated. 
(2) Intravitreal triamcinolone injection 
The subject’s eye was anesthetized with 2% lidocain hyd-
rochloride eye drops, and using 0.05% povidone iodine, the 
palpebra and the eye globe were sterilized. Triamcinolone was 
well shaken (40 mg/1 ml/vial), withdrawn with a 2 ml syringe 
and the needle placed facing the top. The triamcinolone was 
maintained for approximately 30 minutes for complete preci-
pitation. Next, the supernatant was removed and saline in an 
equal amount to the removed supernatant was added, mixed 
well by shaking, and 0.1 ml was withdrawn with a 1 cc syringe. 
After wearing the speculum, using a 30 gauge needle, 4 mg (0.1 
ml) triamcinolone was injected to the vitreous cavity through 
the inferotemporal pars plana, which is distanced from the lim-
bus by 3.5 mm, and antibiotic eye drops administered (Cravit
Ⓡ 
Santen), followed by compressing the adjacent area for approxi-
mately 10 seconds with a sterile cotton swab.
(3) Measurement of corrected BCVA and CMT and 
data analysis 
Baseline and follow-up examination was performed at 1, 3, 
and 6 months after treatment. Using the Snellen chart of the 
patient, best corrected BCVA (logMAR) was measured, intrao-
cular pressure was measured using the Goldman application 
monometer, and using the OCT (STRATUS OCT model 3000, 
Carl Zees, California), CMT was measured 3 times. For the 
change of BCVA and CMT from baseline to the last follow- 
up after treatment, the Wilcox on Signed Rank test was applied, 
and for the comparison of BCVA as well as CMT of the MLG 
group with the MLG+IVTA group, the Mann-Whitney U test 
was applied. Only the IVTA group was retrospectively collected 
and compared with the above 2 groups using one-way ANOVA. 
A p-value of <0.05 was considered to be statistically different. 
The statistics program used was the SPSS program (Ver. 13.0, 
SPSS Inc., Chicago, IL, USA).
Results 
Among 28 patients (30 eyes) of the group treated with the 
MLG therapy, 12 patients (12 eyes) were male, 16 patients (18 
eyes) were female, and the mean age was 59.6 years. The dura-
tion of diabetes was an average of 14.3 years. Among 26 patients 
(30 eyes) of the group treated with the combination of MLG+ 
IVTA, there were 10 male patients (11 eyes) and 16 female pa-
tients (19 eyes), with a mean age of 63.6 years. The duration of 
diabetes was an average of 17.0 years (Table 1). Between the 2 
groups, mean age, the duration of diabetes, intraocular pressure, 
baseline BCVA, and baseline CMT were not statistically signi-
ficantly different. 
The effectiveness of the group treated with the MLG therapy 
was evaluated by the change of BCVA as well as CMT at base-
line and 1, 3, and 6 months after treatment. Baseline BCVA 
was an average of 0.53±0.32, and BCVA at 1 and 3 months 
was 0.51 ±0.29 and 0.50±0.26, respectively. A statistically sig-
nificant improvement of BCVA was not detected (p-value 
=0.255, 0.139). However, 6 months after treatment, the BCVA 
was improved to 0.46±0.19, and was statistically significant 
(p-value=0.01). Baseline CMT was an average of 513.9±55.1 HY Lee, et al. COMBINED THERAPY IN DIABETIC MACULAR EDEMA
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Fig. 1. Graph illustrating BCVA(logMAR) in eyes affected with 
DME. In the MLG+IVTA and IVTA groups, compared with base-
line, values were significantly lower at all time points (Wilcoxon 
signed ranks test). Compared with the MLG group, values for MLG 
+IVTA and IVTA groups were significantly lower at 1 and 3 months 
but had no difference 6 months after treatment. No difference was 
observed between the MLG+IVTA and IVTA groups (one-way 
ANOVA test).
Fig. 2. Graph illustrating central macular thickness (CMT) in eye-
saffected with DME. In the MLG+IVTA and IVTA groups, com-
pared with baseline, values were significantly lower at all time points 
(Wilcoxon signed ranks test). Compared with the MLG, values for 
the MLG+IVTA and IVTA groups were significantly lower at 1 and 
3 months but had no difference 6 months after treatment. No defer-
ence was observed between the MLG+IVTA and IVTA groups (one- 
way ANOVA test).
Table 2. Changes in BCVA (logMAR) obtained with different treatments in eyes affected with DME
BCVA (Best Corrected Visual Acuity) MLG
* group MLG+IVTA
† group p-value
‡
Initial BCVA (logMAR, mean±SD) 0.53±0.32 0.59±0.29 0.417
After 1M BCVA (logMAR, mean±SD) 0.51±0.29 0.31±0.21 0.003
After 3M BCVA (logMAR, mean±SD) 0.50±0.26 0.34±0.17 0.006
After 6M BCVA (logMAR, mean±SD) 0.46±0.19 0.40±0.26 0.058
* MLG=Macular laser grid photocoagulation; 
† MLG+IVTA=Macular laser grid photocoagulation+intravitreal triamcinolone injection group; 
‡ p-value measured by Mann-Whitney U test.
Table 3. Changes in CMT obtained with different treatments in eyes affected with DME
CMT (central macular thickness) MLG
* group MLG+IVTA
† group p-value
‡
Initial CMT (μm, mean±SD) 513.9±55.1 498.2±19.8 0.586
After 1M CMT (μm, mean±SD) 508.9±33.9 465.7±12.1 <0.001
After 3M CMT (μm, mean±SD) 497.6±18.6 455.5±12.3 <0.001
After 6M CMT (μm, mean±SD) 482.8±14.5 478.7±9.0 0.203
* MLG=Macular laser grid photocoagulation; 
† MLG+IVTA=Macular laser grid photocoagulation+intravitreal triamcinolone injection group; 
‡ p-value measured by Mann-Whitney U test.
μm. At 1 and 3 months after treatment, CMT was 508.9±32.9 
μm and 497.6±18.6 μm, respectively, and a statistically sig-
nificant change was not detected (p-value=0.253, 0.172). How-
ever, at 6 months after treatment, CMT was decreased to 482.8 
±14.5 μm, and was statistically significant (p-value=0.002). 
The mean BCVA of the group treated with the combination 
of MLG+IVTA was 0.59±0.29, and the average CMT was 
498.2±19.8 μm. The mean BCVA at 1, 3, and 6 months was 
0.31±0.21, 0.34±0.17, and 0.40 ±0.26 and was significantly 
improved (p-value<0.001, p-value<0.001, p-value<0.001), re-
spectively. The mean CMT at 1, 3, and 6 months after treat-
ment was 465.7±12.1 μm, 455.5±12.3 μm, and 478.7±9.0 μm, 
and all were significantly decreased (p-value<0.001, p-value 
0.001, p-value<0.001), respectively (Fig 1, 2).
The effectiveness was compared by the level of change of 
BCVA and CMT of the 2 groups (MLG and MLG+IVTA). At 
1 and 3 months after treatment, the mean BCVA of the MLG 
+IVTA group had significantly better results than the MLG 
group (p-value=0.003, 0.006). However, at 6 months after treat-
ment, a statistically significant difference between the 2 groups 
was not detected (p-value=0.058) (Table 2).
At 1 and 3 months after treatment, the mean CMT of the MLG 
+IVTA group showed a more statistically significant decrease Korean J Ophthalmol Vol.23, No.3, 2009
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Table 4. Changes in BCVA (logMAR) obtained with different treatments in eyes affected with DME
BCVA (Best Corrected Visual Acuity) MLG
* group MLG+IVTA
† group IVTA
‡ group p-value
§ 
Initial BCVA (logMAR, mean±SD) 0.53±0.32 0.59±0.29 0.54±0.14 0.689
After 1M BCVA (logMAR, mean±SD) 0.51±0.29 0.31±0.21 0.32±0.11 0.001
After 3M BCVA (logMAR, mean±SD) 0.50±0.26 0.34±0.17 0.34±0.10 0.003
After 6M BCVA (logMAR, mean±SD) 0.46±0.19 0.40±0.26 0.40±0.12 0.463
* MLG=Macular laser grid photocoagulation; 
† MLG+IVTA=Macular laser grid photocoagulation+intravitreal triamcinolone injection; 
‡ IVTA=Intravitreal triamcinolone injection; 
§ p-value measured by one-way ANOVA (tukey) test.
Table 5. Changes in CMT obtained with different treatments in eyes affected with DME
Foveal thckness MLG
* group MLG+IVTA
† group IVTA
‡ group p-value
§
Initial CMT (μm, mean±SD) 513.9±55.1 498.2±19.8 506.9±33.1 0.586
After 1M CMT (μm, mean±SD) 508.9±33.9 465.7±12.1 469.2±30.5 <0.001
After 3M CMT (μm, mean±SD) 497.6±18.6 455.5±12.3 455.9±16.5 <0.001
After 6M CMT (μm, mean±SD) 482.8±14.5 478.7±9.0 478.8±17.1 0.203
* MLG=Macular laser grid photocoagulation; 
† MLG+IVTA=Macular laser grid photocoagulation+intravitreal triamcinolone injection; 
‡ IVTA=Intravitreal triamcinolone injection; 
§ p-value measured by one-way ANOVA (tukey) test.
than the MLG group (p-value<0.001, p-value<0.001, respec-
tively), and at 6 months, a statistically significant difference 
between the 2 groups was not detected (p-value=0.203) (Table 3). 
In both groups, no complication that seriously affects BCVA, 
such as retinal detachment, intravitreal hemorrhage, endopthal-
mitis, or epiretinal membrane, developed in any patient after 
treatment. Two weeks after treatment, only 15 eyes out of 60 eyes 
(25%) experienced a temporarily elevated intraocular pressure, 
which was normalized after the use of eye drops for glaucoma. 
During the 6-month follow-up period, no patient from either 
group had cataract surgery.
Additionally, the patients who received the IVTA treatment 
were retrospectively examined and compared with the other 
2 groups (MLG group and MLG+IVTA group). Between the 
MLG and IVTA groups, the IVTA group had better visual 
acuity and CMT results at 1 and 3 months but no significant 
difference at 6 months after treatment. Additionally, between 
the MLG+IVTA and IVTA groups, there was no significant 
visual acuity and CMT difference at 1, 3 and 6 months after 
treatment (Table 4, 5).
Discussion
DME has been shown to be caused by the increase of the 
permeability of retinal capillary blood vessels due to the injury 
of the internal blood-retina barrier caused by diabetes, resulting 
in the leakage of body fluid and plasma components.
1 In addi-
tion, the increase of the secretion of cytokines such as pros-
taglandin within the retina, activation of VEGF and other growth 
factors, abnormality of the retinal pigment epithelium, and trac-
tion of the vitreous body, are thought to be involved in the de-
velopment of DME. The purpose of DME treatment is to prevent 
the deterioration of visual acuity by recovering the thickened 
retina, and occasionally absorb hard exudates. Therefore, even 
if the visual acuity of the patient is good, as a prophylactic 
purpose, immediate treatment is recommended for the invasion 
to the macular center. As to the treatment methods for DME 
reported by the ETDRS, in the 5-year follow-up observation 
period of the group treated with local laser photocoagulation 
therapy, approximately 17% of patients showed improvement 
of visual acuity. Conversely, in the untreated group, only 11% 
of the patients showed improvement of visual acuity.
3 Con-
cerning focal laser photocoagulation therapy, the laser is irra-
diated to the thickened retina, targeting the lesion understood 
to be treatable as assessed by fundus angiography. Distinct hy-
perfluorescence or leakage points can be primarily detected by 
fluorescence angiogram, and if determined to be the cause of 
macular edema, such treatment is effective. However, in the 
diffused type of DME without distinct leakage points on the 
fluorescence angiograph, little improvement is observed. 
MLG therapy performed for DME induces burn in the retinal 
pigment epithelial layer and thus temporarily destroys the lateral 
blood-retina barrier. The adjacent healthy retinal pigment epi-
thelial cells proliferate and replace destroyed cells and thus 
allow recovery as a strong barrier within a few weeks. Inaddi-
tion, MLG therapy destroys a few optical cells, reduces the 
oxygen demand of the retinal lining, and thus reduces edema. 
The shortcoming of this type of MLG therapy is if the edema 
invaded the macular center, deterioration of visual acuity by 
laser therapy may occur, and due to the burn caused by laser, 
an inflammatory reaction is stimulated, and thus the permea-
bility of the retinal capillary blood vessels may be somewhat 
increased.    
Triamcinolone acetonide is a crystal type steroid that has 
been widely used in the field of ophthalmology, and has been 
reported by several studies that intravitreous injection is effec-
tive on the reduction of the macular thickness in DME and the 
improvement of visual acuity.
5-11 Injection of triamcinolone 
is effective on the reduction of a proliferative retinal lesion 
by stabilizing the blood-retina barrier temporarily, which has 
been shown to suppress vascular endothelial growth factors 
that induce the increase of vascular permeability and prosta-HY Lee, et al. COMBINED THERAPY IN DIABETIC MACULAR EDEMA
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glandins that induce inflammatory reactions, thus decreasing 
vascular permeability, and reducing macular edema by the sta-
bilization of the blood-retina barrier, and therefore improving 
visual acuity.
12,13 Diverse dosages of triamcinolone for intra-
vitreal injection from 1 mg up to 25 mg have been attempted. 
Nonetheless, when comparing treatment outcomes, the mini-
mum dosage could minimize side effects, thus, the 4 mg pre-
sently utilized most often in clinics as well as used in the present 
study may be appropriate.
5,6,14 However, triamcinolone injected 
to the vitreous body disappears approximately 3-6 months after 
the absorption of the drug, and the recurrence of macular edema 
afterward has been reported in several studies.
15,16 In the com-
bination therapy of grid laser therapy and triamcinolone injec-
tion, the reaction mechanism of each therapy to macular edema 
is different, hence, not only greater effects on the reduction of 
macular edema can be anticipated but also the stimulation of 
inflammatory reaction induced by grid laser could be prevented 
by the anti-inflammatory reaction of steroids, as  investigated 
in several studies. Choi et al.
17 have reported that in patients 
with simultaneous proliferative diabetic retinopathy and macular 
edema, by the administration of the combination therapy of pan 
retinal photocoagulation and intravitreal injection of triamci-
nolone, macular edema was reduced and the deterioration of 
macular edema caused by photocoagulation was prevented. In 
addition, Jeong et al.
18 have reported that only in DME cases 
with a definite leakage point shown on fluorescence fundus 
angiography, the increased level of visual acuity by local laser 
therapy was higher and the maintenance was more effective. 
However, in DME cases without definite leakage points, laser 
therapy and steroid therapy showed comparable effects on the 
improvement of visual acuity, and for these cases, the combina-
tion of the 2 therapies was thought to possibly be more effective. 
In the present study, both groups (MLG group and MLG+ 
IVTA group) showed significant improvement of corrected 
visual acuity and the reduction of macular thickness on OCT 6 
months after treatment. There was a difference in results bet-
ween the 2 groups at 1 month and 3 months after treatment 
showing the MLG+IVTA group had better results in macular 
thickness as well as corrected visual acuity than the MLG group, 
and thus a rapid recovery rate. However, during the follow-up 
observation at 6 months after treatment, a statistically significant 
difference in corrected visual acuity as well as macular thick-
ness was not shown between the 2 groups. As mentioned above, 
this result may bedue to the concentration of triamcinolone 
decreasing with time and thus decreasing its effect. Therefore, 
for a continuous effect, repeated intravitreal injection of triam-
cinolone is required, although in such cases, the risk of develo-
ping complications is high. The IVTA group had better results 
of visual acuity and CMT than the MLG group at 1 month and 3 
months even though the IVTA group had no significant diffe-
rences 6 months after treatment. In addition, only the IVTA group 
showed no significant differences with the MLG+IVTA group. 
Complications known to be associated with the intravitreal 
injection of triamcinolone include the elevation of intraocular 
pressure, cataract, endophthalmitis, retinal detachment, vitreous 
hemorrhage, retinal venous occlusion, and choroidal hemorrhage 
with the elevation of intraocular pressure reported as the most 
common complication.
19-21 Jonas et al.
5 have reported that in 
52% of patients treated with a 25 mg intraocular injection, in-
traocular pressure was elevated by more than 21 mmHg. Wingate 
et al.
19 have reported that after a 4 mg intraocular injection, 
within 3 months the intraocular pressure was elevated by more 
than 5 mmHg in 30% of the patients. Nevertheless, all patients 
responded well to glaucoma eye drops, and normalized 6 months 
after treatment with no additional treatments required.  
The present study showed similar results to the above- 
mentioned studies where during the follow-up period, the ele-
vation of intraocular pressure higher than 21 mmHg was de-
tected (15 out of 60 eyes; 25%), and all patients were controlled 
by glaucoma eye drop medication. However, in cases treated 
with repeated intravitreal injections, in addition to reversible 
complications such as the elevation of intraocular pressure, 
the risk of developing complications that may cause permanent 
adverse effects on the prognosis of the visual acuity in the future 
such as endophthalmitis and in severe cases blindness, is high. 
Although not detected in the subject groups of the present study, 
in the department of ophthalmology at our hospital, 2 eyes de-
veloped endophthalmitis after intravitreal injection of triam-
cinolone, and even after treatments, the prognosis of visual acuity 
was not favorable. Recently, studies attempting subtenon injec-
tion of triamcinolone in order to avoid the most severe side effects, 
endophthalmitis was performed and the outcomes reported, 
indicating future studies are necessary.
22  
Limitations of the present study include the small number 
of patients in the study subject groups and not considering the 
effect on the progression of cataracts in response to intravitreal 
injection of steroids as assessed by the division of subjects to 
the phakic eyes and the aphakic eyes prior to surgery which may  
influence the results. In addition, because only the IVTA group 
was comprised of retrospective data, comparison with prospec-
tive data (MLG group and MLG+IVTA group) could present 
a bias. 
In conclusion, the present study suggests that the MLG+ 
IVTA therapy had a better effect than the MLG-only treatment 
in the early follow-up time periods but had no difference in 
the late follow-up time periods. Additionally, the IVTA-only 
therapy can be used for an alternative to the combined IVTA 
+MLG therapy, because the IVTA-only treatment had no signi-
ficant difference for all follow-up time periods studied.
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